| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2008 | CA2660374A1 Antiretroviral solid oral composition |
| 02/14/2008 | CA2660356A1 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| 02/14/2008 | CA2660349A1 2-aminobenzoxazole carboxamides as 5ht3 modulators |
| 02/14/2008 | CA2660261A1 Heterocycles useful as inhibitors of carbonic anhydrase |
| 02/14/2008 | CA2660232A1 Structure and use of 5' phosphate oligonucleotides |
| 02/14/2008 | CA2660197A1 Pyrrolo[3,2-d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
| 02/14/2008 | CA2660195A1 2-(heterocyclylbenzyl)pyridazinone derivatives |
| 02/14/2008 | CA2660192A1 Novel enantiomeric pure beta agonists, method of manufacture and use as a medicament thereof |
| 02/14/2008 | CA2660186A1 Pharmaceutical combinations for the treatment of respiratory diseases |
| 02/14/2008 | CA2660168A1 Stable and bioavailable compositions of isomers of carotenoids for skin and hair |
| 02/14/2008 | CA2660133A1 Thiophenecarboxamide derivatives as ep4 receptor ligands |
| 02/14/2008 | CA2660114A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 02/14/2008 | CA2660012A1 Compositions containing chalcones and use thereof |
| 02/14/2008 | CA2659979A1 Reversible inhibition of sperm receptor synthesis for contraception |
| 02/14/2008 | CA2659967A1 Quinazoline derivatives |
| 02/14/2008 | CA2659956A1 Inhibitors of pyruvate kinase and methods of treating disease |
| 02/14/2008 | CA2659894A1 Heteroaryl compounds useful as inhibitors of e1 activating enzymes |
| 02/14/2008 | CA2659774A1 Use of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas |
| 02/14/2008 | CA2659604A1 Pyrimidine derivative as pi3k inhibitor and use thereof |
| 02/14/2008 | CA2659599A1 Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
| 02/14/2008 | CA2659598A1 Amino phosphate derivative and s1p receptor modulator having same as an active ingredient |
| 02/14/2008 | CA2659577A1 Method of treating thermoregulatory disfunction with paroxetine |
| 02/14/2008 | CA2659478A1 Isoform-selective hdac inhibitors |
| 02/14/2008 | CA2659429A1 4-oxo-4,5-dihydropyrrolo[1,2-a]quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| 02/14/2008 | CA2659295A1 Novel hydrate form of o-desmethyl venlafaxine succinate |
| 02/14/2008 | CA2659289A1 Compounds for improving learning and memory |
| 02/14/2008 | CA2659179A1 Stabilization of lorazepam into an orally distegrable dosage form |
| 02/14/2008 | CA2659154A1 An aminoisoquinoline thrombin inhibitor with improved bioavailability |
| 02/14/2008 | CA2658614A1 Pharmaceutical composition containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/norepinephrine recapture in combination |
| 02/14/2008 | CA2658589A1 Mono-and divalent salts of n-(5-hydroxynicotinoil)-l-glutaminic acid exhibiting psychotropic (antidepressant and anxiolytic), neuroprotective, heroprotective and cerebroprotectiveaction |
| 02/14/2008 | CA2658549A1 Oral disintegrating tablet having masked bitter taste and method for production thereof |
| 02/14/2008 | CA2658285A1 Thieno[3,2-c]pyridine-7-carboxylic acid derivatives for use in treating solid tumors |
| 02/14/2008 | CA2658016A1 Use of glucocorticoid receptor antagonists for treatment of infectious conditions |
| 02/14/2008 | CA2657775A1 Purification process of montelukast and its amine salts |
| 02/14/2008 | CA2657017A1 Process for the purification of montelukast |
| 02/14/2008 | CA2655509A1 Steroid-containing sustained release intraocular implants and related methods |
| 02/14/2008 | CA2655472A1 Compositions with enhanced elasticizing activity |
| 02/14/2008 | CA2646901A1 Formulations for parenteral delivery of compounds and uses thereof |
| 02/14/2008 | CA2625476A1 Methods for fabrication of antimicrobial surfaces |
| 02/13/2008 | EP1887082A2 TADG-15: An extracellular serine protease overexpressed in carcinomas |
| 02/13/2008 | EP1887017A1 Prebiotic carbohydrate |
| 02/13/2008 | EP1887008A1 Thienotriazolodiazepine compound and a medicinal use thereof |
| 02/13/2008 | EP1887007A2 Novel compounds |
| 02/13/2008 | EP1887006A1 Polymorphic forms of rosiglitazone base |
| 02/13/2008 | EP1887005A1 Processes for production of optically active ppar-activating compounds and intermediates for production thereof |
| 02/13/2008 | EP1887004A1 Crystalline forms of (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one |
| 02/13/2008 | EP1887003A1 3-[4-heterocyclyl -1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
| 02/13/2008 | EP1887000A1 Arylacetate derivative having isoxazole skeleton |
| 02/13/2008 | EP1886999A2 Bicyclic heteroaromatic compound |
| 02/13/2008 | EP1886998A1 Purification process of montelukast and its amine salts |
| 02/13/2008 | EP1886997A1 Process for the purification of montelukast |
| 02/13/2008 | EP1886996A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| 02/13/2008 | EP1886994A1 Cyclic amine compounds as CCR5 antagonists |
| 02/13/2008 | EP1886993A1 Benzo[f]isoindole derivatives with affinity to the ep4 receptor |
| 02/13/2008 | EP1886990A1 Phenyl-prenyl-ether derivatives for the treatment of cognitive neurodegenerative or neuronal diseases or disorders |
| 02/13/2008 | EP1886719A1 Method of preparing lycopene-enriched formulations that are free of organic solvents, formulations thus obtained, compositions comprising said formulations and use of same |
| 02/13/2008 | EP1886712A1 Compositions for the treatment of chronic degenerative inflammatory conditions |
| 02/13/2008 | EP1886694A1 Peroral formulation of dienogest and ethinylestradiol for contraception |
| 02/13/2008 | EP1886693A1 Agent for regeneration and/or protection of nerves |
| 02/13/2008 | EP1886690A2 Pharmaceutical composition for the treatment of food intolerance |
| 02/13/2008 | EP1886688A1 Method for producing nucleic acid-containing complex preparation |
| 02/13/2008 | EP1886687A1 Intermittent treatment with bone anti-resorptive compounds |
| 02/13/2008 | EP1886686A1 Pharmaceutical composition containing mometasone furoate |
| 02/13/2008 | EP1886685A1 Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| 02/13/2008 | EP1886684A1 Pharmaceutical composition comprising rimonabant |
| 02/13/2008 | EP1886683A1 Novel PPAR ligands that do not cause fluid retention edema or congestive heart failure |
| 02/13/2008 | EP1886682A1 Method for preparation of aqueous doripenem solution |
| 02/13/2008 | EP1886681A2 New nuclear transcription factors regulators |
| 02/13/2008 | EP1886680A1 Maternal supplement |
| 02/13/2008 | EP1886679A2 Methods for controlling highly unsaturated fatty acid content in various tissues |
| 02/13/2008 | EP1886678A1 Stable tablet containing droxidopa |
| 02/13/2008 | EP1886677A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders |
| 02/13/2008 | EP1886676A1 Compositions with enhanced elasticizing activity |
| 02/13/2008 | EP1886674A2 Pharmaceutical composition |
| 02/13/2008 | EP1886673A2 Solid dosage form of enteric solid dispersion and method for producing the same |
| 02/13/2008 | EP1886672A2 Solid dosage form comprising solid dispersion and method for producing the same |
| 02/13/2008 | EP1886670A1 Pharmaceutical compositions of memantine |
| 02/13/2008 | EP1886669A2 Phosphoglucan based immunotrophic preparation for the treatment of adenotonsillar hypertrophy |
| 02/13/2008 | EP1885854A2 Methods and sequences to suppress primate huntington gene expression |
| 02/13/2008 | EP1885851A1 Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases |
| 02/13/2008 | EP1885745A2 Use of h11 protein in in vitro diagnosis of streptococcus pyogenes infections |
| 02/13/2008 | EP1885737A2 6-11 bridged oxime erythromycin derivatives |
| 02/13/2008 | EP1885734A2 Immunogens for meningitidis-a vaccines |
| 02/13/2008 | EP1885725A1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents |
| 02/13/2008 | EP1885724A1 Heterocyclic spiro-compounds as aldosterone synthase inhibitors |
| 02/13/2008 | EP1885723A2 Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| 02/13/2008 | EP1885722A1 Quinoline derivatives as ep4 antagonists |
| 02/13/2008 | EP1885719A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| 02/13/2008 | EP1885717A1 Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases |
| 02/13/2008 | EP1885716A1 Thiazole derivatives and use thereof |
| 02/13/2008 | EP1885713A1 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| 02/13/2008 | EP1885711A1 Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same |
| 02/13/2008 | EP1885710A1 Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| 02/13/2008 | EP1885709A2 Benzofuran derivatives with therapeutic activities |
| 02/13/2008 | EP1885708A2 Gpcr modulators |
| 02/13/2008 | EP1885707A1 A process for the purification of 10-deacetylbaccatine iii from 10-de acet yl-2- debenzoyl-2-pentenoylbaccatine iii |
| 02/13/2008 | EP1885704A2 Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof |
| 02/13/2008 | EP1885702A2 Quinazolinones |
| 02/13/2008 | EP1885699A1 Crystalline form of benzazepinium maleate derivative |
| 02/13/2008 | EP1885697A2 Soluble epoxide hydrolase inhibitors and methods of using same |